<?xml version="1.0" encoding="UTF-8"?>
<ref id="b2-1031825">
 <label>2.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Rosti</surname>
    <given-names>G</given-names>
   </name>
   <name>
    <surname>Castagnetti</surname>
    <given-names>F</given-names>
   </name>
   <name>
    <surname>Gugliotta</surname>
    <given-names>G</given-names>
   </name>
   <name>
    <surname>Baccarani</surname>
    <given-names>M</given-names>
   </name>
  </person-group>
  <article-title>Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom¿</article-title>
  <source>Nat Rev Clin Oncol</source>. 
  <year>2017</year>;
  <volume>14</volume>(
  <issue>3</issue>):
  <fpage>141</fpage>–
  <lpage>154</lpage>.
  <pub-id pub-id-type="pmid">27752053</pub-id>
 </mixed-citation>
</ref>
